[HTML][HTML] Safety and efficacy of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoietin-stimulating agents in treating anemia in renal patients (with or …
N Damarlapally, V Thimmappa, H Irfan, M Sikandari… - Cureus, 2023 - ncbi.nlm.nih.gov
Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a novel group
of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta …
of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta …
Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta‐Analysis of Randomized Controlled Trials including 6,518 Patients
J Lei, H Li, S Wang - BioMed research international, 2022 - Wiley Online Library
Background. Roxadustat is a newly listed oral hypoxia‐inducible factor‐proline enhancing
enzyme inhibitor (HIF‐PHI) in recent years. There have been some studies that have proved …
enzyme inhibitor (HIF‐PHI) in recent years. There have been some studies that have proved …
Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis
M Wu, C Zang, F Ma, B Chen, J Liu, Z Xu - Clinical and Experimental …, 2022 - Springer
Background Anaemia is a common complication of end-stage renal disease (ESRD) that
relies on dialysis. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) is a new …
relies on dialysis. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) is a new …
[HTML][HTML] Effect of roxadustat versus erythropoietin (EPO) for treating anemia in patients with diabetic kidney disease: a retrospective cohort study
L Zhang, Y Liu, Y Huang, Y Zhao, C Wei… - Annals of …, 2022 - ncbi.nlm.nih.gov
Background Renal anemia of diabetic kidney disease (DKD) shows higher incidence rate,
earlier onset and higher severity than other chronic kidney disease (CKD). Roxadustat, an …
earlier onset and higher severity than other chronic kidney disease (CKD). Roxadustat, an …
[HTML][HTML] Roxadustat: Do we know all the answers?
QY Li, QW Xiong, X Yao, F Liu, X Tang… - Biomolecules and …, 2023 - ncbi.nlm.nih.gov
Anemia is a common complication of chronic kidney disease (CKD), and its prevalence rises
as the disease progresses. Intravenous or subcutaneous erythropoiesis-stimulating agents …
as the disease progresses. Intravenous or subcutaneous erythropoiesis-stimulating agents …
Renal anemia: Current treatments and emerging molecules
M Heras-Benito - Revista Clínica Española (English Edition), 2023 - Elsevier
Anemia is a common complication of kidney disease and the prevalence increases as the
disease progresses. It worsens the quality of life of patients and increases morbidity and …
disease progresses. It worsens the quality of life of patients and increases morbidity and …
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing …
Q Zheng, P Zhang, H Yang, Y Geng, J Tang, Y Kang… - Heliyon, 2023 - cell.com
Aims This study aimed to evaluate the effects of hypoxia-inducible factor prolyl hydroxylase
inhibitors (HIF-PHIs) on iron metabolism and inflammation in dialysis-dependent chronic …
inhibitors (HIF-PHIs) on iron metabolism and inflammation in dialysis-dependent chronic …
[PDF][PDF] Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
X Tang, F Liu, Q Li, J Mao - Kidney Diseases, 2023 - karger.com
Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral
agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating …
agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating …
Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study
Y Wang, X Yu - Kidney Dis, 2024 - karger.com
Background: Anemia is one of the common complications of chronic kidney disease (CKD),
and its prevalence has been arising globally. The key cause of anemia in CKD patients is …
and its prevalence has been arising globally. The key cause of anemia in CKD patients is …
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease
JT Ha, S Hiremath, M Jun, SC Green… - NEJM …, 2024 - evidence.nejm.org
Background Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral
treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta …
treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta …